NCT01033487View on ClinicalTrials.gov

A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Pulmonary Disease, Chronic ObstructiveLung DiseasesRespiratory Tract DiseasesChronic Obstructive Airway DiseaseCOPD
Interventions
DRUG

placebo

oral inhaled formulation, single dose

DRUG

active comparator

oral inhaled formulation, single dose

DRUG

Low Dose PF-03635659

oral inhaled formulation, single dose, low dose

DRUG

Mid Dose PF-03635659

oral inhaled formulation, single dose, mid dose

DRUG

High Dose PF-03635659

oral inhaled formulation, single dose, high dose

Trial Locations (1)

10117

Pfizer Investigational Site, Berlin

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY